Slazinic Acid

Slazinic Acid

SCHEMBL3801772

Cc1cc(O)c(C=O)c2c1C(=O)Oc1c(CO)c(O)c3c(c1O2)C(O)OC3=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 1.00
KDM4E B2RXH2 4/20 1.00
MEN1 O00255 4/20 1.00
ALDH1A1 P00352 4/20 1.00
KMT2A Q03164 4/20 1.00
TDP1 Q9NUW8 4/20 1.00
THRB P10828 3/20 1.00
RECQL P46063 3/20 1.00
USP2 O75604 3/20 1.00
POLB P06746 2/20 1.00
L3MBTL1 Q9Y468 2/20 1.00
GAA P10253 1/20 1.00
CACNA1B Q00975 1/20 1.00
APBA1 Q02410 1/20 1.00
CYP3A4 P08684 5/20 0.77
HPGD P15428 3/20 0.77
PHPT1 Q9NRX4 2/20 0.77
ALOX12 P18054 2/20 0.77
CASP1 P29466 1/20 0.77
MED25 Q71SY5 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17694852 0.93 KDM4E (0.87) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL15581642 0.92 MAPT (0.85) MAPTKDM4EMEN1ALDH1A1KMT2A
Norstictic Acid SCHEMBL29369714 0.87 MAPT (1.00) MAPTKDM4EMEN1ALDH1A1KMT2A
Norstictic Acid SCHEMBL13287269 0.87 MAPT (1.00) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL30509240 0.87 KDM4E (0.76) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL15581643 0.78 KDM4E (0.66) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL17988248 0.78 MAPT (0.72) MAPTKDM4EMEN1ALDH1A1KMT2A
Stictic Acid SCHEMBL13495711 0.76 KDM4E (1.00) MAPTKDM4EMEN1ALDH1A1KMT2A
Stictic Acid SCHEMBL29394416 0.76 KDM4E (1.00) MAPTKDM4EMEN1ALDH1A1KMT2A
SCHEMBL17975303 0.75 MAPT (0.65) MAPTKDM4EMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9750742-B2 Small molecular inhibitors of RAD51 recombinase and methods thereof DREXEL UNIVERSITY (US) 2017-09-05 US claimed
US-20160106751-A1 SMALL MOLECULAR INHIBITORS OF RAD51 RECOMBINASE AND METHODS THEREOF DREXEL UNIVERSITY (US) 2016-04-21 US claimed
US-20140080849-A1 Small Molecular Inhibitors of RAD51 Recombinase and Methods Thereof Philadelphia Health & Education Ccorporation d/b/a Drexel University College of Medicine (US) 2014-03-20 US claimed
JP-2223520-A None JP disclosed
US-20250368695-A1 Atranorin biosynthesis gene derived from lichens and uses thereof INDUSTRY ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIV (KR) 2025-12-04 US disclosed
WO-2022260402-A1 ATRANORIN BIOSYNTHESIS GENE DERIVED FROM LICHEN AND USE THEREOF 순천대학교 산학협력단 2022-12-15 WO disclosed
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (US) 2019-02-19 US disclosed
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (US) 2019-02-19 US disclosed
CN-108391659-A A kind of plant transpiration resistant agent and preparation method thereof 天津市德宇生物工程技术有限公司 2018-08-14 CN disclosed
US-9750742-B2 Small molecular inhibitors of RAD51 recombinase and methods thereof DREXEL UNIVERSITY (US) 2017-09-05 US disclosed
US-9750742-B2 Small molecular inhibitors of RAD51 recombinase and methods thereof DREXEL UNIVERSITY (US) 2017-09-05 US disclosed
CN-101798244-A Multifunctional transpiration inhibitor BEIJING GREEN SINGLARITY SCIENCE & TECHNOLOGY DEV CO LTD 2010-08-11 CN disclosed
CN-101731277-A Method for preparing plant transpiration suppression material and using method thereof ENVIRONMENT AND SUSTAINABLE DE 2010-06-16 CN disclosed
CN-101417901-A Multifunctional antitranspirant and preparation method thereof BEIJING LUSEQIDIAN TECHNOLOGY (CN) 2009-04-29 CN disclosed
EP-1675020-A2 Parser Xerox Corporation (US) 2006-06-28 EP disclosed
US-20060136196-A1 Bi-dimensional rewriting rules for natural language processing XEROX CORPORATION 2006-06-22 US disclosed
CN-1500520-A Lichen bacteriophage and its production method thereof 大兴安岭林格贝有机食品有限责任公司 2004-06-02 CN disclosed
JP-H02223520-A VASODILATOR COMPRISING DEPSIDONE KAO CORP 1990-09-05 JP disclosed
US-4937195-A SYMBIOTIC ASSOCIATION OF FUNGUS CELL AND ALGAL CELL NIPPON PAINT CO., LTD. (JP) 1990-06-26 US disclosed
US-4536474-A SYMBIOTIC MIXTURE OF ALGAE AND FUNGI NIPPON PAINT CO., LTD. (JP) 1985-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160106751-A1 SMALL MOLECULAR INHIBITORS OF RAD51 RECOMBINASE AND METHODS THEREOF RAD51, MRE11, BRCA1 MAPT 3439/4885KDM4E 2087/4885MEN1 1277/4885
US-20140080849-A1 Small Molecular Inhibitors of RAD51 Recombinase and Methods Thereof RAD51, MRE11, BRCA1 MAPT 3439/4885KDM4E 2087/4885MEN1 1277/4885
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease BAK1, SSB, MRE11 MAPT 3931/4885KDM4E 2402/4885MEN1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.